U.S. biotech company Regeneron posted full-year 2022 net attributable profit of $4.338 billion (€4.006 billion), a 46.3 percent contraction from 2021 earnings of $8.075 billion (€7.457 billion).
Revenues, on the other hand, reached 12.173 billion dollars (11.242 billion euros), representing a 24.3 percent decline compared to the previous year’s turnover of 16.072 billion dollars (14.842 billion euros) due to a 43 percent reduction in sales.
In addition, in the fourth quarter alone, net profit reached 1,197 million dollars (1,105 million euros), compared to a positive balance of 2,229 million dollars (2,058 million euros) a year earlier, down 46.3 percent year-on-year, according to the company.
Meanwhile, quarterly revenue was $3.414 billion (€3.153 billion), down 31.1 percent compared to revenue of $4.952 billion (€4.573 billion) in 2021.
Source: (EUROPA PRESS)
